DCGI to Implement Stricter Quality Audits While Expanding Test-Licence Waivers for Medical Device Manufacturers

What Happened

The Drug Controller General of India (DCGI) has announced a two-pronged regulatory initiative targeting the medical device manufacturing sector. First, the authority plans to implement significantly more rigorous audit procedures for device manufacturers, including enhanced pre-approval inspections and ongoing compliance monitoring. Second, and counterbalancing this tightening, DCGI intends to expand its test-licence waiver programme, which would allow certain manufacturers to bypass preliminary testing requirements during the approval phase, contingent upon demonstrated compliance history and quality management systems certification.

While specific implementation timelines and detailed criteria have not been formally published in the announcement, industry sources suggest the stricter audit protocols may take effect within the next 12–18 months. The test-licence waiver expansion is expected to benefit manufacturers already holding ISO 13485 certification or equivalent international quality standards, as well as those with documented track records of regulatory compliance across jurisdictions.

This regulatory shift aligns with the DCGI's broader mandate to strengthen India's position as a credible and quality-conscious medical device hub, particularly as domestic manufacturers seek to compete with international players and expand exports.

Why It Matters

For compliance professionals and audit teams within medical device organisations, this announcement signals a fundamental recalibration of the DCGI's enforcement posture. Enhanced audit intensity will require manufacturers to substantially elevate their quality management documentation, traceability systems, and regulatory record-keeping. The DCGI's audit approach has historically focused on post-market surveillance; a shift toward pre-approval and ongoing periodic audits suggests the regulator is adopting a more preventive, continuous-oversight model.

Simultaneously, the test-licence waiver programme offers genuine commercial relief for organisations meeting stringent eligibility criteria. Traditional test-licence phases can extend product development timelines by 6–12 months; bypassing this stage for pre-qualified manufacturers meaningfully accelerates time-to-market and reduces associated carrying costs for regulatory and testing infrastructure.

This dual mechanism also reflects a global trend in medical device regulation: risk-proportionate oversight. Higher-risk device categories and first-time applicants will face more intensive scrutiny, whilst established players with proven compliance systems gain expedited pathways. For CFOs and finance teams, this creates distinct cost-benefit scenarios: investment in quality systems and compliance infrastructure now yields tangible approval timeline benefits later.

For the broader industry, this signals DCGI's confidence in market-led quality mechanisms (ISO certification, third-party audits) whilst retaining direct regulatory authority over final approval decisions. This reduces the perception of arbitrary regulatory delays whilst maintaining safety gates.

Practical Impact

Manufacturers seeking test-licence waivers should immediately audit their ISO 13485 certification status and compliance documentation across all previous regulatory submissions globally. Finance teams should budget for enhanced internal audit capabilities and possibly external audit firm retainers to ensure readiness for DCGI's stricter examination protocols.

Compliance and quality teams must anticipate increased document requests, facility inspections, and technical interrogations during the approval process. Standard operating procedures, batch records, change management logs, and deviation reports should be consolidated and cross-referenced to facilitate rapid response to auditor queries.

Organisations without international quality certification should prioritise ISO 13485 acquisition, as this will likely become a de facto requirement for accessing expedited pathways under future amendments. The cost of certification (₹2–8 lakhs depending on device complexity) is offset by regulatory timeline savings.

For financial reporting purposes, manufacturers should evaluate whether enhanced regulatory timelines affect revenue recognition policies under Ind AS 115, particularly where regulatory approval gates determine performance obligations. Longer approval cycles may require deferral of revenue recognition or adjustment of contract asset provisions.

Third-party audit firms and compliance consultants will see increased demand for quality system strengthening, mock audits, and regulatory gap analysis services. For multi-device manufacturers with varying compliance histories, DCGI audits may now be tiered by product risk profile, requiring segmented quality oversight strategies.

Key Takeaways

• →Manufacturers must strengthen ISO 13485 certification and quality management documentation immediately to remain competitive under the new stricter audit regime
• →Test-licence waivers are available only to pre-qualified applicants; eligibility criteria should be verified with DCGI or regulatory consultants before commencing approval applications
• →Budget for enhanced internal audit capacity and external compliance support; DCGI's more intensive oversight model will increase resource demands during approval and post-approval phases
• →Finance teams should review revenue recognition policies under Ind AS 115 to account for potential changes in approval timelines and regulatory decision gates
• →Prioritise international regulatory compliance documentation and traceability systems; DCGI audits will likely examine regulatory history across multiple jurisdictions as a quality indicator

Disclaimer: This update is for general information only and does not constitute legal, tax or professional advice. Regulatory positions may change. Please consult APRA & Associates LLP for advice specific to your business. Contact us.